Loading
NASDAQHealthcareDrug Manufacturers - General
Latest quote
$14.04
−$0.35 · -2.43%
Amarin Corporation plc is a pharmaceutical firm dedicated to the research, development, and commercialization of therapeutic solutions for cardiovascular diseases. Its operations span several international regions, including the United States, Germany, Canada, Lebanon, and the United Arab Emirates. The company's flagship product is VASCEPA, an omega-3 fatty acid formulation available by prescription only. This medication acts as an adjunctive therapy to diet, designed to decrease elevated triglyceride levels in adult patients suffering from severe hypertriglyceridemia. Amarin primarily distributes its offerings through wholesale channels and specialized pharmacy providers. Furthermore, the company has entered into a collaboration with Mochida Pharmaceutical Co., Ltd. to advance the development and market introduction of drug products and new indications derived from Vascepa's active pharmaceutical ingredient, which encompasses omega-3 acid and eicosapentaenoic acid. Established in 1989 as Ethical Holdings plc, the organization rebranded to Amarin Corporation plc in 1999. Its corporate headquarters are located in Dublin, Ireland.
Previous close
$14.04
−$0.35 · -2.43%
After-hours
$14.04
$0.00 · 0.00%
Sep 10, 7:30 PM ET
Regular session · ET · Market data may be delayed.
Amarin Corporation plc is a pharmaceutical firm dedicated to the research, development, and commercialization of therapeutic solutions for cardiovascular diseases. Its operations span several international regions, including the United States, Germany, Canada, Lebanon, and the United Arab Emirates. The company's flagship product is VASCEPA, an omega-3 fatty acid formulation available by prescription only. This medication acts as an adjunctive therapy to diet, designed to decrease elevated triglyceride levels in adult patients suffering from severe hypertriglyceridemia. Amarin primarily distributes its offerings through wholesale channels and specialized pharmacy providers. Furthermore, the company has entered into a collaboration with Mochida Pharmaceutical Co., Ltd. to advance the development and market introduction of drug products and new indications derived from Vascepa's active pharmaceutical ingredient, which encompasses omega-3 acid and eicosapentaenoic acid. Established in 1989 as Ethical Holdings plc, the organization rebranded to Amarin Corporation plc in 1999. Its corporate headquarters are located in Dublin, Ireland.
Day range
Current $14.04
52-week range
Current $14.04
Regular session · ET · Market data may be delayed.
GoAI Score
Hold
Valuation
48
Fair Value
Sentiment
52
Mixed
Risk
43
Elevated Risk
Momentum
40
Weakening
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
Amarin Corporation plc is a pharmaceutical firm dedicated to the research, development, and commercialization of therapeutic solutions for cardiovascular diseases. Its operations span several international regions, including the United States, Germany, Canada, Lebanon, and the United Arab Emirates. The company's flagship product is VASCEPA, an omega-3 fatty acid formulation available by prescription only. This medication acts as an adjunctive therapy to diet, designed to decrease elevated triglyceride levels in adult patients suffering from severe hypertriglyceridemia. Amarin primarily distributes its offerings through wholesale channels and specialized pharmacy providers. Furthermore, the company has entered into a collaboration with Mochida Pharmaceutical Co., Ltd. to advance the development and market introduction of drug products and new indications derived from Vascepa's active pharmaceutical ingredient, which encompasses omega-3 acid and eicosapentaenoic acid. Established in 1989 as Ethical Holdings plc, the organization rebranded to Amarin Corporation plc in 1999. Its corporate headquarters are located in Dublin, Ireland.
Day range
Current $14.04
52-week range
Current $14.04
Profitability as a percentage of reported revenue.
Revenue
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 213.65M USD | 228.61M USD | 306.91M USD | 369.19M USD | 583.19M USD |
| Cost of goods sold | 92.78M USD | 147.23M USD | 141.37M USD | 126.71M USD | 121.33M USD |
| Gross profit | 120.87M USD | 81.38M USD | 165.54M USD | 242.48M USD | 461.86M USD |
| Research and development | 19.81M USD | 20.87M USD | 22.22M USD | 30.41M USD | 29.31M USD |
| Selling, general, and administrative | 115M USD | 152.31M USD | 199.94M USD | 304.42M USD | 408.33M USD |
| Operating expenses | 134.81M USD | 173.18M USD | 222.16M USD | 348.35M USD | 451.36M USD |
| Interest income | 10.85M USD | 13.4M USD | 11.86M USD | 2.82M USD | 1.22M USD |
| Interest expense | 7K USD | 7K USD | 8K USD | 15K USD | 129K USD |
| Depreciation and amortization | 3.03M USD | 3.01M USD | 2.97M USD | 3.1M USD | 2.86M USD |
| Operating income | −13.94M USD | −91.8M USD | −56.62M USD | −105.87M USD | 10.5M USD |
| Net income | −38.8M USD | −82.18M USD | −59.11M USD | −105.8M USD | 7.73M USD |
Company facts updated Sep 11, 2026.
Recent quarterly results
Recent quarterly results
Third-party consensus; not a GoAI recommendation.
Funds reporting this stock among their holdings, ordered by reported position size.
AI-generated and delayed market data for informational and educational purposes only. Not investment advice.
